Araccel signs agreement to provide eClinical Trial Solutions to undisclosed pharma

“With a staff that has been involved in more than 10 compounds achieving successful NDA Approval, we understand that when a new technology is implemented into a clinical trial there is a certain

By Editor on Jan 31, 2002

With a staff that has been involved in more than 10 compounds achieving successful NDA Approval, we understand that when a new technology is implemented into a clinical trial there is a certain amount of hand-holding that needs to take place, said James Conklin, CEO of Araccel. Araccel has both the clinical and technology experience to ensure that our clients are comfortable with the technology and that Araccel products will work the way they expect.

Araccel revealed its Solutions Platform v2.2 was developed to create a seamless transition from paper-based to technology-based clinical trials. Furthermore, the platform also is designed to enable companies to utilize the system for nearly any clinical trial, whether paper-based or electronic.